Stock MIPH MINAPHARM PHARMACEUTICALS
Add to a list
To use this feature you must be a member
Log inSign up

MINAPHARM Pharmaceuticals Stock

Equities

MIPH

EGS380G1C011

Pharmaceuticals

End-of-day quote Egyptian Exchange
Other stock markets
 06:00:00 2024-04-17 pm EDT 		5-day change 1st Jan Change
225.5 EGP 0.00% Intraday chart for MINAPHARM Pharmaceuticals 0.00% +3.58%
Apr. 07 MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI

Financials

Sales 2022 3.62B 74.99M Sales 2023 3.89B 80.62M Capitalization 2.41B 49.89M
Net income 2022 613M 12.7M Net income 2023 -32M -663K EV / Sales 2022 0.71 x
Net Debt 2022 740M 15.32M Net Debt 2023 1.86B 38.54M EV / Sales 2023 1.1 x
P/E ratio 2022
2.88 x
P/E ratio 2023
-43.5 x
Employees -
Yield 2022
1.89%
Yield 2023
-
Free-Float 27.3%
More Fundamentals * Assessed data

Chart MINAPHARM Pharmaceuticals

Dynamic Chart

Latest news about MINAPHARM Pharmaceuticals

MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023 CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Bioventure, Minapharm Pharmaceuticals and Migentra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2021 CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
MINAPHARM Pharmaceuticals Reports Consolidated Earnings Results for the Six Months Ended June 30, 2021 CI
MINAPHARM Pharmaceuticals Reports Standalone Earnings Results for the Six Months Ended June 30, 2021 CI
MINAPHARM Pharmaceuticals Announces Consolidated Earnings Results for the Quarter Ended March 31, 2021 CI
ProBioGen AG and MINAPHARM Pharmaceuticals Incorporate MiGenTra GmbH - A Healthcare Transforming Medicines Company CI
RDIF and Minapharm Agree to Produce over 40 Million Doses of the Sputnik V Vaccine in Egypt CI
More news

Press releases MINAPHARM Pharmaceuticals

SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries AQ
SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries This landmark MOU marks a significant step towards ensuring national health security and achieving biomanufacturing autonomy in Saudi Arabia AQ
Participants Dosed of Adessia® in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa AQ
Participants Dosed of Adessia® in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa This follows a prior announcement made by Minapharm Pharmaceuticals on February 13, 2023 reporting that said Phase 1 trial received unconditional approval from the Paul-Ehrlich Institut (PEI) AQ
Bioventure, Minapharm Pharmaceuticals and MiGenTra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa AQ
More press releases

Quotes and Performance

Current month-6.96%
1 month-6.96%
3 months-4.82%
6 months+10.54%
Current year+3.58%
More quotes

Highs and lows

1 week
216.32
Extreme 216.32
224.93
1 month
208.00
Extreme 208
258.99
Current year
208.00
Extreme 208
294.70
1 year
190.00
Extreme 190
294.70
3 years
84.00
Extreme 84
294.70
5 years
64.00
Extreme 64
294.70
10 years
25.70
Extreme 25.7
294.70
More quotes

Managers and Directors - MINAPHARM Pharmaceuticals

Managers TitleAgeSince
Shaheer Wafeeq Sa'ad Al-Bardissy CEO
 Chief Executive Officer - -
Wafik Saad El-Bardissy CEO
 Chief Executive Officer - -
Rafiq Raymond DFI
 Director of Finance/CFO - -
Members of the board TitleAgeSince
Amr Mohamed Sobhi Hamza El-Shabrawishy BRD
 Director/Board Member - -
Wafik Saad El-Bardissy CEO
 Chief Executive Officer - -
Anwar Nasr Mekhaeel BRD
 Director/Board Member - -
More insiders

Quotes

Date Price Change Volume
24-04-18 225.5 0.00% 328
24-04-17 225.5 0.00% 61
24-04-16 225.5 0.00% 105

End-of-day quote Egyptian Exchange, April 17, 2024

More quotes

Company Profile

Minapharm Pharmaceuticals S.A.E. specializes in developing, manufacturing and marketing prescription pharmaceutical products. The products are for the treatment of gastroenterological, ophthalmologic, cardiovascular, genetic, dermatological, orthopedic diseases, etc.
Sector
Pharmaceuticals
More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

1st Jan change Capi.
MINAPHARM PHARMACEUTICALS Stock MINAPHARM Pharmaceuticals
+3.58% 51.62M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+20.91% 43.54B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+16.96% 21.74B
SANDOZ GROUP AG Stock Sandoz Group AG
+9.05% 13.53B
CIPLA LIMITED Stock Cipla Limited
+7.98% 13.02B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+33.80% 11.28B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-11.05% 6.99B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+6.64% 5.09B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. MIPH Stock